Back to Search
Start Over
The rationale for using low-molecular weight heparin in the therapy of symptomatic COVID-19 patients.
- Source :
- Open Medicine; Jan2022, Vol. 17 Issue 1, p216-220, 5p, 1 Color Photograph, 1 Graph
- Publication Year :
- 2022
-
Abstract
- Accumulated evidence suggest that the adverse outcome of severe coronavirus disease 2019 (COVID-19) is closely related to prothrombotic microvascular pathology with a high risk of venous thromboembolism. Furthermore, the first observational studies indicated that adjunct therapy with low-molecular weight heparin (LMWH) was associated with lower mortality in this cohort of patients. However, the timing of starting LMWH and the dose remain controversial in COVID-19 patients. Considering the above, the aim of this study was to reveal the rationale for using LMWH in the therapy of symptomatic COVID-19 patients based on experimental and clinical studies on LMWH in inflammatory settings with special consideration given to randomized trials. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 23915463
- Volume :
- 17
- Issue :
- 1
- Database :
- Complementary Index
- Journal :
- Open Medicine
- Publication Type :
- Academic Journal
- Accession number :
- 178839825
- Full Text :
- https://doi.org/10.1515/med-2021-0374